post-splenectomy vaccine prophylaxis - SurgicalCriticalCare.net

DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They
are intended to serve as a general statement regarding appropriate patient care practices based upon the available medical
literature and clinical expertise at the time of development. They should not be considered to be accepted protocol or policy, nor are
intended to replace clinical judgment or dictate care of individual patients.
POST-SPLENECTOMY VACCINE PROPHYLAXIS
SUMMARY
The splenectomized patient should be vaccinated to decrease the risk of overwhelming postsplenectomy
sepsis (OPSS) due to organisms such as Streptococcus pneumoniae, Haemophilus influenzae type B,
and Neisseria meningitidis. Patients should be educated prior to discharge on the risk of OPSS and their
immunocompromised state. An understanding of the need for prompt medical attention should be
instilled in such patients to reduce the morbidity and mortality of postsplenectomy infection.
RECOMMENDATIONS
• Level 1
‣ None
• Level 2
‣ Non-elective splenectomy patients should be vaccinated on or after postoperative day 14.
‣ Asplenic patients should be revaccinated at the appropriate time interval for each vaccine.
• Level 3
‣ Elective splenectomy patients should be vaccinated at least 14 days prior to the operation.
‣ Asplenic or immunocompromised patients (with an intact, but nonfunctional spleen) should be
vaccinated as soon as the diagnosis is made.
‣ Pediatric vaccination should be performed according to the recommended pediatric dosage
and vaccine types with special consideration made for children less than 2 years of age.
‣ When adult vaccination is indicated, the following vaccinations should be administered:
o Streptococcus pneumoniae
• Polyvalent pneumococcal vaccine (Pneumovax 23)
o Haemophilus influenzae type B
• Haemophilus influenzae b vaccine (HibTITER)
o Neisseria meningitidis
• Age 16-55: Meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid
conjugate vaccine (Menactra)
• Age >55: Meningococcal polysaccharide vaccine (Menomune-A/C/Y/W-135)
Vaccine Dose Route Revaccination
Polyvalent pneumococcal 0.5 mL SC* Every 6 years
Quadravalent meningococcal/diphtheria conjugate 0.5 mL IM upper deltoid Every 3-5 years †
Quadravalent meningococcal polysaccharide 0.5 mL SC* Every 3-5 years
Haemophilus b conjugate 0.5 mL IM* None
*Administered in the deltoid or lateral thigh region.
† Contact the manufacturer for the latest recommendations prior to revaccination.
EVIDENCE DEFINITIONS
• Class I: Prospective randomized controlled trial.
• Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case
control studies.
• Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion.
• Technology assessment: A technology study which does not lend itself to classification in the above-mentioned format.
Devices are evaluated in terms of their accuracy, reliability, therapeutic potential, or cost effectiveness.
LEVEL OF RECOMMENDATION DEFINITIONS
• Level 1: Convincingly justifiable based on available scientific information alone. Usually based on Class I data or strong Class II
evidence if randomized testing is inappropriate. Conversely, low quality or contradictory Class I data may be insufficient to
support a Level I recommendation.
• Level 2: Reasonably justifiable based on available scientific evidence and strongly supported by expert opinion. Usually
supported by Class II data or a preponderance of Class III evidence.
• Level 3: Supported by available data, but scientific evidence is lacking. Generally supported by Class III data. Useful for
educational purposes and in guiding future clinical research.
1

INTRODUCTION
Blunt abdominal trauma commonly injures the spleen resulting in either irreparable parenchymal
disruption (necessitating removal of the injured organ) or devascularization of varying degrees. Nonoperative
management may avoid splenectomy, but can also result in functional asplenia if the
devascularization is extensive or therapeutic embolization of a portion or all of the spleen is required.
Elective splenectomy may be indicated for specific primary disease of the spleen. Loss of functional
splenic tissue places such individuals at high risk for infection by encapsulated organisms such as
Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis. Although the
risk of fulminant septicemia or meningitis as a result of infection by such organisms appears to be less in
the adult population (by virtue of prior exposure to these bacteria), overwhelming postsplenectomy sepsis
(OPSS) remains a significant concern in the asplenic patient (1).
The incidence of OPSS is estimated to occur in 0.05% to 2% of splenectomized patients (2). It may
develop immediately or as late as 65 years postsplenectomy (2-4). Mortality is significant and reported to
be as high as 50% (4,5). OPSS incidence reduction is dependent upon (2,5-7):
1) Prophylactic education of the patient and physician as to its risk and prevention
2) Rapid recognition of the asplenic individual when infection is suspected
Reduced post-splenectomy levels of opsonins, splenic tuftsin, and immunoglobulin (IgM) (which promote
phagocytosis of particulate matter and bacteria), hamper the body’s ability to clear encapsulated
organisms (4,6,7). Vaccination, to impart immunity against such infections, is commonly performed
despite the absence of Class I or Class II data to support its efficacy. As 50 to 90% of OPSS infections
are secondary to Streptococcus pneumoniae infection, the polyvalent pneumococcal vaccine has been
the most commonly administered postsplenectomy vaccine. In recent years, the meningococcal and
Haemophilus influenzae type b vaccines have also been advocated (2-17).
Timing of vaccine administration following splenectomy has been the topic of a longstanding debate. Two
major concerns include the patients’ immunogenicity in the perioperative period and the impaired immune
function of the critically ill (2,13,16,17). The patient’s present state of health should be considered prior to
the administration of postsplenectomy vaccines. In patients with moderate to severe acute illness,
vaccination should be delayed until the illness has resolved. This minimizes adverse effects of the
vaccine which could be more severe in the presence of illness or could confuse the patient’s clinical
picture (such as a post-vaccine fever) (16).
All of the vaccines cause adverse reactions which are generally self-limiting and resolve 24-72 hours after
vaccine administration. The polyvalent pneumococcal vaccine causes a transient and self-limited fever
(in 5% of vaccinated patients), as well as pain and redness at the site for 1-2 days. A hypersensitivity
reaction can occur at the injection site of the Haemophilus influenzae type b vaccine along with
occasional fever, aches, and malaise. Both meningococcal vaccines can cause headaches, fatigue,
malaise and injection site reactions.
There are two meningococcal vaccines currently on the market: the meningococcal polysaccharide
vaccine (Menomune A/C/Y/W-135) and the meningococcal (groups A, C, Y, W-135) polysaccharide
diphtheria toxoid conjugate (Menactra). Both products provide the same level of immunity against
Neisseria meningitidis. Differences between the two products are as follows (29-32):
1) Menactra is for intramuscular injection only, Menomune is administered subcutaneously.
2) Menactra is a conjugated vaccine (adding the diphtheria toxoid).
3) Menomune requires revaccination every 3-5 years. Long-term data with Menactra is not yet
available. The manufacturer, Sanofi Pasteur, has data demonstrating adequate levels for up to 3-
5 years (similar to Menomune). Due to on-going duration studies, it is recommended by the
manufacturer that healthcare providers contact Sanofi-Pasteur prior to revaccination in order to
obtain the most current information.
4) Menactra is approved only for use in adolescents and adults between the ages of 11 and 55 (14-
16,25-27) Menactra has applied for a license for use in children ages 2-10 years of age. There is
currently no data on adults > 55 years of age.
2 Approved 1/7/03
Revised 10/17/06

LITERATURE REVIEW
Two Class I studies have demonstrated that the polyvalent pneumococcal vaccine results in the highest
antibody titers, for the most common serotypes, when administered 14 days postsplenectomy (16,17).
These prospective, randomized trials evaluated the efficacy of the vaccine when administered at 1, 7, 14,
and 28 days postsplenectomy. As these trials were designed to demonstrate the immunogenicity of the
vaccines and not the prevention of OPSS, they can only be used to advocate timing of vaccination.
In 2004, Landgren et.al. published a prospective study on antibody response to repeated vaccination.
This study included 28 (out of 311) post-trauma splenectomized patients. Their results showed that time
between splenectomy and first pneumococcal vaccine was not associated with pre-vaccination, peak or
follow-up antibody levels. 25 of the 28 trauma patients received their 1 st vaccine post-splenectomy. A
major limitation of this study is that the time from splenectomy to first vaccine was only documented in
24% of the cases, yet they claimed that timing had no effect (18). Similarly, Grimfors et.al. conducted a
longitudinal study of 173 patients (33 trauma) for three years. Pneumococcal antibody responses
declined to pre-treatment values at three years in all groups. They also found no correlation between the
interval from splenectomy to vaccination and response to vaccination. The data to support this
conclusion was not published (19).
Schreiber et.al., published a study in rats in 1998 looking at timing of vaccination and subsequent ability
to survive pneumococcal challenge. There was no difference in ability to survive a pneumococcal
challenge between rats vaccinated on post-operative day 1, 7, or 42 (20). In another study, Werner et.al.
looked at the effect of perioperative hypovolemic shock and response to vaccination and found no
difference if splenectomized rats were vaccinated on post-operative day 1, 7, or 28. Both of these studies
raise the question of whether delaying vaccination for 14 days as suggested in the Shatz et.al. studies is
necessary (21). Further human studies are needed to address the timing of post-splenectomy vaccines.
Class II data supports the vaccination of asplenic patients based on studies of the spleen’s role in
immune function and its ability to provide defense against encapsulated organisms (5). Current Center for
Disease Control (CDC) recommendations for post-splenectomy vaccinations include the polyvalent
pneumococcal (Pneumovax 23), the meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria
toxoid conjugate (Menactra, for patients ages 11-55) or the meningococcal polysaccharide (Menomune
A/C/Y/W-135, ages 55), and the Haemophilus influenzae type b vaccines (Hib TITER) (12-14,25-
28). All three of these vaccines may be administered simultaneously (15).
Revaccination needs have been established by Class II studies of immune antibody levels and efficacy
after initial vaccination (3). Patients receiving the pneumococcal vaccine should be revaccinated 5 years
later (28). Patients who receive the meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135)
should be revaccinated every 3-5 years (12-14, 26, 27). Patients who receive the meningococcal (groups
A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra) probably should be
revaccinated every 3-5 years. However, long-term studies are currently on-going and the manufacturer,
Sanofi-Pasteur, suggests contacting them (1-570-839-7187) for the latest recommendations prior to
revaccination. The Haemophilus influenzae type b vaccine does not require revaccination (12-14).
There is no Class I data identifying the appropriate timing for pre-splenectomy Haemophilus,
Pneumococcal or Meningococcal vaccination for patients with nonfunctional or diseased spleens.
Vaccination two weeks prior to surgery is commonly practiced, but this is supported only by Class III data
(16, 17). Pre-splenectomy vaccination has been demonstrated to induce antibody formation in both
adults and children (18). The types of antibody produced and time to antibody formation (generally 1 to 4
weeks) does vary from patient to patient. (18-20). The antibody titer required to prevent either
pneumococcal carriage or disease is unknown and has been extrapolated from data obtained from the
literature on Haemophilus influenzae titers (21). In the elective splenectomy patient, therefore,
vaccination as soon as splenic disease is diagnosed appears prudent to allow time for antibody
production (13). The CDC has outlined recommendations for both initial vaccination in the pediatric
population as well as booster (revaccination) requirements in patients with an anatomically present, but
non-functional spleen (23).
3 Approved 1/7/03
Revised 10/17/06

The CDC recommends that asplenic travelers contact an international health clinic or the CDC
(www.cdc.gov) to obtain information on disease risks within the intended country of travel. Asplenic
travelers should be advised of the increased risk for Meningococcal meningitis and recommendation of
the A and C vaccine for all asplenic individuals traveling to sub-Saharan Africa, India, and Nepal.
REFERENCES
1. King H, Schumacher HB. Splenic studies: I. Susceptibility to infection after splenectomy in infancy.
Ann Surg 1952; 136(2):239-242.
2. Shatz DV. Vaccination practices among North American trauma surgeons in splenectomy for trauma.
J Trauma 2002; 53:950-956.
3. Rutherford EJ, Livengood J, Higginbotham M, et.al. Efficacy and safety of pneumococcal
revaccination after splenectomy for trauma. J Trauma 1995; 39:448-452.
4. Dickerman JD. Traumatic asplenia in adults. Arch Surg 1981; 116:361-363.
5. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin
Microbial Infect 2001; 7:657-60.
6. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventative
measures are not be followed. J Clin Pathology 2001; 54:214-218.
7. Brigden ML, Pattulo AL. Prevention and management of overwhelming postsplenectomy infection –
an update. Crit Care Med 1999; 27:836-42.
8. Spickett GP, Bulliore J, Wallis J, et.al. Northern region asplenia register – analysis of first two years. J
Clin Pathology 1999; 52:424-429.
9. Williams DN, Bhavjot K. Postsplenectomy care strategies to decrease the risk of infection. Postgrad
Med 1996: 100: 195-8,201,205.
10. Sumaraju V, Smith LG, Smith SM. Infectious complications in asplenic hosts. Infect Dis Clin N
America 2001; 15:551-65.
11. Styrt B. Infections associated with asplenia: risks, mechanisms, and prevention. Am J Med 1990;
88:33N-42N.
12. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on
Immunization Practices (AICP). MMWR 2000; 49(RR-07):1-3.
13. Prevention and management of infections in patients without a spleen. Clin Micro and Infect 2001;
12:657-680.
14. Recommendations of the Advisory Committee on Immunization Practices (AICP): Use of vaccines
and immune globulins in persons with altered immunocompetence. MMWR 1993; 42(RR-04):1-18.
15. General recommendations on immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR
2002; 51(RR-2):1-36.
16. Shatz DV, Romero-Steiner S, Elie CM, et.al. Antibody responses in postsplenectomy trauma patients
receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J
Trauma 2002; 53:1037-1042.
17. Shatz DV, Schinsky MF, Pais LB, et.al. Antibody responses in postsplenectomy trauma patients
receiving the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after
splenectomy. J Trauma 1998; 44(6):760-766.
18. Landgren O, Bjoerkholm M, Konradsen HB, et.al. A prospective study on antibody response to
repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with
special reference to Hodgkin’s lymphoma. J Intern Med 2004;255:644-673.
19. Grimfors G, Soederqvist M, Holm G, et.al. A longitudinal study of class and subclass antibody
response to pneumococcal vaccination in splenectomized individuals with special reference to
Hodgkin’s disease. Eur J Haematol 1990;45:101-108.
20. Schreiber MA, Pusateri AE, Veit BC, et.al. Timing of vaccination does not affect antibody response or
survival after pneumococcal challenge in splenectomized rats. J Trauma 1998;45(4):692-697.
21. Werner AM, Katner HP, Vogel R, et.al. Delayed vaccination dos not improve antibody responses in
splenectomized rats experiencing hypovolemic shock. Am Surg 2001;67(9):834-838.
22. Klinge J, Hammersen G, Scharf J, et.al. Overwhelming postsplenectomy infection with vaccine-type
Streptococcus pneumoniae in a 12-year-old girl despite vaccination and antibiotic prophylaxis.
Infection 1997; 25:368-371.
4 Approved 1/7/03
Revised 10/17/06

23. Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with
sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect
Dis 192; 14:1124-1136.
24. Siber GR, Gorham C, Martin P, et.al. Antibody response to pretreatment immunization and posttreatment
boosting with bacterial polysaccharide vaccines in paitents with Hodgkin’s disease. Ann
Intern Med 1986; 104:467-475.
25. Hosea SW, Burch CG, Brown EJ, et.al. Impaired immune response of splenectomized patients to
polyvalent pneumococcal vaccine. Lancet 1981; 1:804-807.
26. Cimaz R, Mensi C, D’Angelo E, et.al. Safety and immunogenicity of a conjugate vaccine against
Haemophilus influenzae type b in splenectomized and nonsplenectomized patients with Cooley
anemia. J Infect Dis 2001; 183:1819-1821.
27. Jockovich M, Menednhall NP, Sombeck MD, et.al. Long-term complications of laparotomy in
Hodgkin’s disease. Ann Surg 1994; 219:615-621.
28. CDC: Preventing pneumococcal disease among infants and young children. MMWR 2000; 49:1-38.
29. Meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine:
Menactra ® . Package Insert. Sanofi Pasteur. 2005 Dec: 1-10. www.menactra.com [Accessed 08-28-
2006].
30. Meningococcal polysaccharide vaccine. Drug Shortage Bulletin. ASHP. 2006 May 22. www.ashp.org
[Accessed 08-28-2006].
31. Meningococcal conjugate vaccine (MCV-4): AICP Recommendation. National Infection Prevention.
CDC 2006. www.cdc.gov/nip/vaccine/mening/mcv4/mcv4_aicp.htm [Accessed 08-28-2006].
32. Revisions to the general recommendations on immunizations. CDC 2006 Sept. www.cdc.gov
[Accessed 08-28-2006]. PowerPoint presentation.
5 Approved 1/7/03
Revised 10/17/06

POSTSPLENECTOMY PATIENT INFORMATION SHEET
Name:
Splenectomy (splee-nek-tuh-mee) is the name of the operation that was done to remove your spleen.
The spleen is a fist-sized organ located in the upper left side of your abdomen (belly). The spleen helps
you fight infections, get rid of old or damaged red blood cells, and store blood for your body. Because of
either disease or damage to your spleen, it had be removed. You can live without a spleen, but you may
be at a higher risk for certain types of blood infection. To help you fight these infections in the future, you
have been given the following immunizations (shots):
□ Pneumococcal vaccine, polyvalent (Pneumovax 23)
**Revaccinate every 6 years**
□ Age > 55: Meningococcal polysaccharide vaccine
(Menomune A/C/Y/W-135) **Revaccinate every 3-5 years**
□ Age 16-55: Meningococcal polysaccharide/diphtheria toxoid conjugate vaccine
(Menactra A/C/Y/W-135) **May need revaccination every 3-5 years**
□ Haemophilus influenzae type b conjugate vaccine
**No revaccination needed**
Date:
Date:
Date:
Date:
It is important that you go and see a doctor IMMEDIATELY if you have any of the following symptoms:
• Fever
• Chills
• Abdominal pain
• Skin rash, swelling, redness, or infection
• Diarrhea
• Achy or weak feeling
• Cough
• Vomiting
These are signs that you may have an infection. Without your spleen, a small or minor infection my
become very serious and your doctor needs to examine you and possibly start antibiotics to help your
body fight the infection. Always check with your doctor before any dental or invasive procedures, as you
may need to take antibiotics before the procedure.
The effect of the vaccines in preventing infection varies from patient to patient and depends on the
strength of your immune system when the vaccines were given. You will need to be re-immunized (have
the shots again) approximately every 5 years for the rest of your life. You should make sure that your
doctor has a copy of this information sheet so that they can help remind you when it is time to be reimmunized.
If you or your doctor have any questions about the above information, you should contact your
surgeon:
Surgeon’s Name:
Surgeon’s Phone Number:
6 Approved 1/7/03
Revised 10/17/06